Works matching IS 01676997 AND DT 2021 AND VI 39 AND IP 3

Results: 30
    1

    Advances in anti-BRAF therapies for lung cancer.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 879, doi. 10.1007/s10637-021-01068-8
    By:
    • Roviello, Giandomenico;
    • D'Angelo, Alberto;
    • Sirico, Marianna;
    • Pittacolo, Matteo;
    • Conter, Felipe Umpierre;
    • Sobhani, Navid
    Publication type:
    Article
    2
    3
    4
    5

    Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer.

    Published in:
    2021
    By:
    • Inoue, Hiroto;
    • Ono, Akira;
    • Kawabata, Takanori;
    • Mamesaya, Nobuaki;
    • Kawamura, Takahisa;
    • Kobayashi, Haruki;
    • Omori, Shota;
    • Wakuda, Kazushige;
    • Kenmotsu, Hirotsugu;
    • Naito, Tateaki;
    • Murakami, Haruyasu;
    • Yasui, Kazuaki;
    • Ogawa, Hirofumi;
    • Onoe, Tsuyoshi;
    • Endo, Masahiro;
    • Harada, Hideyuki;
    • Takahashi, Toshiaki
    Publication type:
    Correction Notice
    6

    Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 853, doi. 10.1007/s10637-020-01060-8
    By:
    • Sugimoto, Takeya;
    • Fujimoto, Daichi;
    • Sato, Yuki;
    • Tamiya, Motohiro;
    • Yokoi, Takashi;
    • Tamiya, Akihiro;
    • Iwasawa, Shunichiro;
    • Hata, Akito;
    • Uchida, Junji;
    • Fukuda, Yasushi;
    • Hara, Satoshi;
    • Kanazu, Masaki;
    • Hirano, Katsuya;
    • Kokubo, Masaki;
    • Yamamoto, Nobuyuki
    Publication type:
    Article
    7
    8
    9
    10
    11
    12

    Potent synergistic anti-tumor activity of a novel humanized anti-HER2 antibody hersintuzumab in combination with trastuzumab in xenograft models.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 697, doi. 10.1007/s10637-020-01048-4
    By:
    • Shiravi, Fariba;
    • Mohammadi, Mehdi;
    • Golsaz-Shirazi, Forough;
    • Bahadori, Tannaz;
    • Judaki, Mohammad Ali;
    • Fatemi, Forough;
    • Zare, Hengameh Ahmadi;
    • Haghighat, Farzaneh Notash;
    • Mobini, Maryam;
    • Jeddi-Tehrani, Mahmood;
    • Amiri, Mohammad Mehdi;
    • Shokri, Fazel
    Publication type:
    Article
    13
    14
    15
    16
    17
    18
    19

    Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 644, doi. 10.1007/s10637-020-01040-y
    By:
    • Dell'Anno, Irene;
    • Martin, Sarah A.;
    • Barbarino, Marcella;
    • Melani, Alessandra;
    • Silvestri, Roberto;
    • Bottaro, Maria;
    • Paolicchi, Elisa;
    • Corrado, Alda;
    • Cipollini, Monica;
    • Melaiu, Ombretta;
    • Giordano, Antonio;
    • Luzzi, Luca;
    • Gemignani, Federica;
    • Landi, Stefano
    Publication type:
    Article
    20
    21

    Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 812, doi. 10.1007/s10637-020-01038-6
    By:
    • Quinn, David I.;
    • Tsao-Wei, Denice D.;
    • Twardowski, Przemyslaw;
    • Aparicio, Ana M.;
    • Frankel, Paul;
    • Chatta, Gurkamal;
    • Wright, John J.;
    • Groshen, Susan G.;
    • Khoo, Stella;
    • Lenz, Heinz-Josef;
    • Lara, Primo N.;
    • Gandara, David R.;
    • Newman, Edward
    Publication type:
    Article
    22
    23
    24

    Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 785, doi. 10.1007/s10637-020-01035-9
    By:
    • Wu, J.;
    • Liu, D.;
    • Offin, M.;
    • Lezcano, C.;
    • Torrisi, J. M.;
    • Brownstein, S.;
    • Hyman, D. M.;
    • Gounder, M. M.;
    • Abida, W.;
    • Drilon, A.;
    • Harding, J. J.;
    • Sullivan, R. J.;
    • Janku, F.;
    • Welsch, D.;
    • Varterasian, M.;
    • Groover, A.;
    • Li, B. T.;
    • Lacouture, M. E.
    Publication type:
    Article
    25
    26
    27

    NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 736, doi. 10.1007/s10637-020-01028-8
    By:
    • Scopim-Ribeiro, Renata;
    • Machado-Neto, João Agostinho;
    • Eide, Christopher A.;
    • Coelho-Silva, Juan Luiz;
    • Fenerich, Bruna Alves;
    • Fernandes, Jaqueline Cristina;
    • Scheucher, Priscila Santos;
    • Savage Stevens, Samantha L.;
    • de Melo Campos, Paula;
    • Olalla Saad, Sara T.;
    • de Carvalho Palma, Leonardo;
    • de Figueiredo-Pontes, Lorena Lobo;
    • Simões, Belinda Pinto;
    • Rego, Eduardo Magalhães;
    • Tognon, Cristina E.;
    • Druker, Brian J.;
    • Traina, Fabiola
    Publication type:
    Article
    28
    29
    30

    TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 3, p. 724, doi. 10.1007/s10637-020-01019-9
    By:
    • Miura, Akihiro;
    • Sootome, Hiroshi;
    • Fujita, Naoya;
    • Suzuki, Takamasa;
    • Fukushima, Hiroto;
    • Mizuarai, Shinji;
    • Masuko, Norio;
    • Ito, Kimihiro;
    • Hashimoto, Akihiro;
    • Uto, Yoshihiro;
    • Sugimoto, Tetsuya;
    • Takahashi, Hidekazu;
    • Mitsuya, Morihiro;
    • Hirai, Hiroshi
    Publication type:
    Article